Evidence map›Paper›PMID 41142965›Full record

ArticleInternational journal of pharmaceutics: X2025

Self-healing hydrogel loaded with M2pep-modified recombinant apoferritin enhanced chemotherapy in hepatocellular carcinoma

Jiayi Qin, Pei Chen, Xin Li, Qingsong Tang, Qingwei Zhao, Haiqin Huang, Yangbo Zhu

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiayi QinDepartment of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Pei ChenDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Xin LiDepartment of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Qingsong TangDepartment of Pharmaceutics, School of Pharmacy, Nantong University, Nantong 226001, China.
Qingwei ZhaoDepartment of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Haiqin HuangDepartment of Pharmaceutics, School of Pharmacy, Nantong University, Nantong 226001, China.
Yangbo ZhuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy plays an important role in the clinical systemic management of advanced hepatocellular carcinoma (HCC). However, the efficacy of chemotherapy is remarkably suppressed by the tumor microenvironment. After observing the prevalent M2-tumor associated macrophages (TAMs) in clinical HCC specimen, we developed a dual protein drug delivery system, namely, genetically engineered M2 macrophage targeting peptide (M2pep) modified recombinant apoferritin (HFn) for the delivery of "old drug" chloroquine (CQ), and bovine serum albumin (BSA) for the delivery of PTX for the synergistic treatment of HCC. To avoid additional efficacy limitations caused by systemic exposure, BSA@PTX and M2-HFn@CQ were incorporated into a self-healing hydrogel (COT@BP/M2HC) composed of carboxymethyl chitosan, oxidized sodium alginate and tannic acid. The experimental results demonstrated this COT@BP/M2HC hydrogel had good biocompatibility and biodegradability, adhesion, injectability and self-healing properties. It was further confirmed that a single peritumoral injection of COT@BP/M2HC successfully promoted the polarization of M2 TAMs to M1 TAMs, and the M1/M2 ratio increased by 4.63 times compared with the BSA@PTX group, thereby achieving 74.7 % tumor growth inhibition in HCC tumor-bearing mouse models. These findings revealed a potential TAM polarizing effect of CQ and provided a reliable combination strategy for improving HCC chemotherapy efficacy.

Indexed as

ApoferritinCombination therapyCOT@BP/M2HC hydrogelHepatocellular carcinomaTumor associated macrophage reprogramming

Identifiers

PMID41142965
PMCPMC12547206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.